Top 5 Construction Material Stocks For 2017

The Wall Street Journal reported that government regulators are pushing back against Anthem’s (ANTM) purchase of Cigna (CI). California, however, seems to have few issues with the proposed combination of Aetna (AET) andHumana (HUM). Leerink’s Ana Gupte explains:

The Department of Managed Care (DMHC) has been reported to have approved theAetna-Humana deal, according to a tweet from Chad Terhune of Kaiser Health News. While California is not a critical State for the deal given Humana’s small presence, it is another indication that the merger anti-trust review is on track with only four States remaining for approval. The news is also significant in light of the recent pushback Anthem is being reported to face from California’s Department of Insurance Commissioner David Jones. We would be looking to see if Anthem (OP) also receives approval for the Cigna (OP) deal from the DMHC which is an important catalyst given Anthem and Cigna have meaningful market share overlap in the state. We reiterate our 80+% probability of Aetna-Humana close and our OP rating onAetna and Humana.

Top 5 Construction Material Stocks For 2017: Syngenta AG(SYT)

Syngenta AG, an agribusiness company, engages in the discovery, development, manufacture, and marketing of a range of products designed to enhance crop yields and food quality worldwide. The company operates in three segments: Crop Protection, Seeds, and Business Development. The Crop Protection segment offers herbicides for corn, cereals, soybean, and rice; fungicides for corn, cereals, fruits, grapes, rice, soybean, and vegetables; insecticides for fruits, vegetables, and field crops; seed care for corn, soybean, cereals, and cotton; and professional products, such as products for public health, and turf and ornamentals. This segment markets its products through independent distributors and dealers, agricultural consultants, and growers. The Seeds segment develops, produces, and markets seeds and plants based on advanced genetics and related technologies. This segment provides approximately 200 product lines and approximately 6,800 varieties of proprietary genetics, incl uding vegetables, flowers, corn, soybean, sugar beet, and sunflower primarily under the NK, Golden Harvest, Garst, HILLESHG, S&G, Rogers, Zeraim Gedera, and Fischer brand names. The Business Development segment engages in the development of enzymes and traits to enhance agronomic, nutritional, and biofuel properties of plants. The company was founded in 1999 and is headquartered in Basel, Switzerland.

Advisors’ Opinion:

  • [By Vanina Egea]

    The battle on the field continues. Monsanto (MON) and Syngenta (SYT) are expected to enter the seed business with a strong bid. Both companies stand at the top of the agricultural inputs industry, and continue to look for ways to improve performance. Let us see what some gurus think about their future prospects, and if they see them fit for a long term investment.

Top 5 Construction Material Stocks For 2017: Cal-Maine Foods, Inc.(CALM)

 

Cal-Maine Foods, Inc. produces, grades, packages, markets, and distributes shell eggs. It offers specialty shell eggs, such as nutritionally enhanced, cage free, organic, and brown eggs under the Egg-Lands Best, Land O Lake, Farmhouse, and 4-Grain brand names, as well as under private labels. The company sells its products to various customers, including national and regional grocery store chains, club stores, foodservice distributors, and egg product consumers primarily in the southeastern, southwestern, mid-western, and mid-Atlantic regions of the United States. Cal-Maine Foods, Inc. was founded in 1969 and is based in Jackson, Mississippi.

Advisors’ Opinion:

  • [By Manikandan Raman]

    © 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

      Related Articles (CALM)

Hot International Companies To Watch In Right Now: Myriad Genetics, Inc.(MYGN)

Myriad Genetics, Inc. (Myriad), incorporated on November 6, 1992, is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Myriad offers diagnostic tests for a range of dise ases, such as Myriad myRisk Hereditary Cancer test for hereditary breast cancer, hereditary ovarian cancer, hereditary pancreatic cancer, hereditary uterine (endometrial) cancer and hereditary colon cancer; Myriad myPlan Lung Cancer test for lung cancer; Myriad myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis (RA).

Molecular Diagnostic Testing

The Company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins. Myriad’s primary molecular diagnostic tests include myRisk Hereditary Cancer, a deoxyribonucleic acid (DNA) sequencing test for assessing the risks for hereditary cancers, such as breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer; BRACAnalysis, a DNA sequencing test for assessing the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx ! , a DNA sequencing test for use as a companion diagnostic with the poly (ADP-ribose) polymerase (PARP) inhibitor LynparzaTM (olaparib); Tumor BRACAnalysis CDx, a DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum-based chemotherapy agents and PARP inhibitors; COLARIS, a DNA sequencing test for assessing the risk of colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for assessing the risk of colorectal cancer; Vectra DA, a protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a ribonucleic acid (RNA) expression test for assessing the aggressiveness of prostate cancer; EndoPredict, an RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, an RNA expression test for diagnosing melanoma, and myPlan Lung Cancer, an RNA expression test for assessing the aggressiveness of lung cancer.

Pharmaceutical and Clinical Services

The Company provides a range of pharmaceutical and clinical services. Through its subsidiary, Myriad RBM, Inc., Myriad provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology and medical research industries utilizing its multiplexed immunoassay technology. The Company also owns Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG, located approximately 15 miles from the Company’s European laboratories in Munich, Germany. The Company’s technology enables it to screen sets of well-characterized clinical samples from both diseased and non-diseased populations against its menu of biomarkers.

Advisors’ Opinion:

  • [By Ben Levisohn]

    We took in Walt Disney (DIS) earnings, Argus’ downgrade of Noble (NE), and Myriad Genetics’ (MYGN) freefall.

    We looked at the speculation that International Paper (IP) could be a takeover target, and the progress made at Ralph Lauren (RL), and the slowing same-store sales at Shake Shack (SHAK).

Top 5 Construction Material Stocks For 2017: Sotheby's(BID)

 

Sothebys operates as an auctioneer of authenticated fine art, decorative art, jewelry, wine, and collectibles in the United States, the United Kingdom, China, France, Switzerland, and internationally. The company operates through two segments, Agency and Finance. The Agency segment accepts property on consignment; and matches buyers and sellers of authenticated fine art, decorative art, jewelry, wine, and collectibles through the auction or private sale process. It is also involved in the sale of artworks; and operation of an auction house for investment-quality automobiles. The Finance segment offers art-related financing services to various collectors and art dealers. This segment provides secured loans, including advances secured by consigned property to borrowers who are contractually committed to sell the property in the near term; and general purpose term loans secured by property not presently intended for sale. The c ompany is also involve d in the retail wine operations; licensing Sothebys International Realty and related trademarks; and licensing its Sothebys brand name for use in connection with the art auction business in Australia, and art education n services in the United States and the United Kingdom. Sothebys was founded in 1744 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Sotheby’s (BID) has climbed 5.3% to $34 after the auction house’s earnings and revenue topped Street estimates.

    Tyson Foods (TSN) has gained 3.5% to $76.20 after beating earnings forecasts and raising its full-year guidance.

  • [By Marshall Hargrave]

    Now Loeb's looking to put that capital to work in other markets, with the art market being a perfect candidate. Loeb and his Third Point hedge fund have started their latest activist campaign with leading auction house Sotheby's (NYSE: BID). Loeb joins fellow activist investor Marcato Capital in the stock.

Top 5 Construction Material Stocks For 2017: BanColombia S.A.(CIB)

 

Bancolombia S.A. provides various banking products and services to individual, corporate, and government customers. The company operates through ten segments: Banking Colombia, Banking El Salvador, Leasing, Trust, Investment Banking, Brokerage, Banking Panama, Insurance, Off Shore, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, overdrafts, and financing for industrial projects; mortgage banking and factoring services; and financial and operating leasing services. The company also provides capital market products, such as futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers asset management products, such as mutual funds, private equity funds, and privately managed investment accounts; cash management services; foreign currency transaction services; and bancassurance and insurance services. Further, the company provides investment banking services, such as financial advisory, underwriting services, capital market services, and private equity management services; and trust services, such as money market accounts, mutual and pension funds, private equity funds, payment trust, custody services, and corporate trust. Additionally, it offers loan management, transportation, and real estate brokerage services; and is involved in outsourcing activities. As of December 31, 2015, it had 1,274 branches. The company also operates 5,080 automatic teller machines. Bancolombia S.A. was founded in 1945 and is headquartered in Medell铆n, Colombia.

Advisors’ Opinion:

  • [By Matt Smith]

    Bancolombia appears attractively priced
    Another Colombian company that appears under-valued is the Andean country’s largest commercial bank Bancolombia (NYSE: CIB  ) . For the year-to-date Bancolombia’s share price fell 17% because of a weak second quarter bottom-line. This decline was primarily caused by the bank’s net income plunging by 41% year-over-year because of mark-to-market losses caused by the value lost in the bank’s securities portfolio.